Evidence map›Paper›PMID 21152046›Full record

ArticlePloS one2010

The "Phantom Effect" of the Rexinoid LG100754: structural and functional insights.

Yoshiteru Sato, Nick Ramalanjaona, Tiphaine Huet, Noelle Potier, Judit Osz, Pierre Antony, Carole Peluso-Iltis, Pierre Poussin-Courmontagne, Eric Ennifar, Yves Mély and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 73 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Increased Molecular Flexibility Widens the Gap betweenACS medicinal chemistry letters · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Retinoid X Receptor Antagonists.International journal of molecular sciences · 2018
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Yoshiteru SatoDépartement de Biologie et de Génomique Structurales, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Institut National de Santé et de Recherche Médicale (INSERM) U964/Centre National de Recherche Scientifique (CNRS) UMR 1704/Université de Strasbourg, Illkirch, France.
Nick Ramalanjaona
Tiphaine Huet
Noelle Potier
Judit Osz
Pierre Antony
Carole Peluso-Iltis
Pierre Poussin-Courmontagne
Eric Ennifar
Yves Mély
Annick Dejaegere
Dino Moras
Natacha Rochel
Institut de génétique et de biologie moléculaire et cellulaire · FRCentre National de la Recherche Scientifique · FRInserm · FRUniversité de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinoic acid receptors (RARs) and Retinoid X nuclear receptors (RXRs) are ligand-dependent transcriptional modulators that execute their biological action through the generation of functional heterodimers. RXR acts as an obligate dimer partner in many signalling pathways, gene regulation by rexinoids depending on the liganded state of the specific heterodimeric partner. To address the question of the effect of rexinoid antagonists on RAR/RXR function, we solved the crystal structure of the heterodimer formed by the ligand binding domain (LBD) of the RARα bound to its natural agonist ligand (all-trans retinoic acid, atRA) and RXRα bound to a rexinoid antagonist (LG100754). We observed that RARα exhibits the canonical agonist conformation and RXRα an antagonist one with the C-terminal H12 flipping out to the solvent. Examination of the protein-LG100754 interactions reveals that its propoxy group sterically prevents the H12 associating with the LBD, without affecting the dimerization or the active conformation of RAR. Although LG100754 has been reported to act as a 'phantom ligand' activating RAR in a cellular context, our structural data and biochemical assays demonstrate that LG100754 mediates its effect as a full RXR antagonist. Finally we show that the 'phantom ligand effect' of the LG100754 is due to a direct binding of the ligand to RAR that stabilizes coactivator interactions thus accounting for the observed transcriptional activation of RAR/RXR.

Indexed as

AnimalsBinding, CompetitiveBinding SitesFluorescence PolarizationHumansLigandsMiceModels, MolecularProtein BindingProtein MultimerizationProtein Structure, TertiaryReceptor Cross-TalkReceptors, Retinoic AcidRecombinant ProteinsRetinoic Acid Receptor alphaRetinoidsLG 100754LigandsRARA protein, humanRara protein, mouseReceptors, Retinoic AcidRecombinant ProteinsRetinoic Acid Receptor alphaRetinoidsRetinoid X ReceptorsTetrahydronaphthalenesTretinoin

Identifiers

PMID21152046
PMCPMC2994906
OpenAlexW2044226073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.